期刊
MOLECULAR NEUROBIOLOGY
卷 53, 期 4, 页码 2733-2749出版社
SPRINGER
DOI: 10.1007/s12035-015-9544-0
关键词
Alzheimer; Human; Inflammation; Lipoxin; Maresin; Microglia; Neuroprotection; Omega-3; Resolvin; SPMs
资金
- Swedish Research Council [22743, 22744]
- Swedish Brain Power
- Chinese Scholarship Council, P.R. China
- Knut and Alice Wallenberg Foundation
- Karolinska Institutet research funds
- Stiftelsen for Gamla Tjanarinnor
- Swedish Alzheimer Foundation
- Gun och Bertil Stohnes Stiftelse
- Barmore Fund (MUSC)
- National Institutes of Health [P01GM095467, GM038765, R21AG048631-01A1]
Inflammation in the brain is a prominent feature in Alzheimer's disease (AD). Recent studies suggest that chronic inflammation can be a consequence of failure to resolve the inflammation. Resolution of inflammation is mediated by a family of lipid mediators (LMs), and the levels of these specialized pro-resolving mediators (SPMs) are reduced in the hippocampus of those with AD. In the present study, we combined analysis of LMs in the entorhinal cortex (ENT) from AD patients with in vitro analysis of their direct effects on neurons and microglia. We probed ENT, an area affected early in AD pathogenesis, by liquid chromatography-tandem mass spectrometry (LC-MS-MS), and found that the levels of the SPMs maresin 1 (MaR1), protectin D1 (PD1), and resolvin (Rv) D5, were lower in ENT of AD patients as compared to age-matched controls, while levels of the pro-inflammatory prostaglandin D-2 (PGD(2)) were higher in AD. In vitro studies showed that lipoxin A(4) (LXA(4)), MaR1, resolvin D1 (RvD1), and protectin DX (PDX) exerted neuroprotective activity, and that MaR1 and RvD1 down-regulated beta-amyloid (A beta)(42)-induced inflammation in human microglia. MaR1 exerted a stimulatory effect on microglial uptake of A beta(42). Our findings give further evidence for a disturbance of the resolution pathway in AD, and indicate that stimulating this pathway is a promising treatment strategy for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据